CTOs on the Move

Rainier Therapeutics

www.rainierrx.com

 
Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rainierrx.com
  • 1040 Davis Street #202
    San Leandro, CA USA 94577
  • Phone: 925.413.6140

Executives

Name Title Contact Details

Similar Companies

Sierra By The Sea

Sierra by the Sea is a beachfront residential drug addiction rehab & mental health treatment facility. Offering evidence-based addiction treatment for adults.

Tweed

Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.

Integrum

Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

MD Communications Group

MD Communications Group is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.